PL3079671T3 - Rozpadająca się w jamie ustnej stała jednostka dawkowania zawierająca składnik estetrolowy - Google Patents

Rozpadająca się w jamie ustnej stała jednostka dawkowania zawierająca składnik estetrolowy

Info

Publication number
PL3079671T3
PL3079671T3 PL14814804T PL14814804T PL3079671T3 PL 3079671 T3 PL3079671 T3 PL 3079671T3 PL 14814804 T PL14814804 T PL 14814804T PL 14814804 T PL14814804 T PL 14814804T PL 3079671 T3 PL3079671 T3 PL 3079671T3
Authority
PL
Poland
Prior art keywords
dosage unit
solid dosage
unit containing
orally disintegrating
disintegrating solid
Prior art date
Application number
PL14814804T
Other languages
English (en)
Inventor
Johannes Jan Platteeuw
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Donesta Bioscience B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3079671(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Donesta Bioscience B.V. filed Critical Donesta Bioscience B.V.
Publication of PL3079671T3 publication Critical patent/PL3079671T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14814804T 2013-12-12 2014-12-10 Rozpadająca się w jamie ustnej stała jednostka dawkowania zawierająca składnik estetrolowy PL3079671T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13196904 2013-12-12
EP14814804.2A EP3079671B1 (en) 2013-12-12 2014-12-10 Orally disintegrating solid dosage unit containing an estetrol component
PCT/EP2014/077127 WO2015086643A1 (en) 2013-12-12 2014-12-10 Orally disintegrating solid dosage unit containing an estetrol component

Publications (1)

Publication Number Publication Date
PL3079671T3 true PL3079671T3 (pl) 2018-03-30

Family

ID=49759137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14814804T PL3079671T3 (pl) 2013-12-12 2014-12-10 Rozpadająca się w jamie ustnej stała jednostka dawkowania zawierająca składnik estetrolowy

Country Status (29)

Country Link
US (2) US9884064B2 (pl)
EP (1) EP3079671B1 (pl)
JP (1) JP6447931B2 (pl)
KR (1) KR102265150B1 (pl)
CN (1) CN105979935B (pl)
AU (1) AU2014363599B2 (pl)
BR (1) BR112016013502B1 (pl)
CA (1) CA2932855C (pl)
CL (1) CL2016001411A1 (pl)
CY (1) CY1119817T1 (pl)
DK (1) DK3079671T3 (pl)
EA (1) EA032306B1 (pl)
ES (1) ES2655076T3 (pl)
HR (1) HRP20180129T1 (pl)
HU (1) HUE035848T2 (pl)
IL (1) IL246082B (pl)
LT (1) LT3079671T (pl)
MA (1) MA39105B1 (pl)
MX (1) MX369035B (pl)
NO (1) NO3079671T3 (pl)
NZ (1) NZ720906A (pl)
PL (1) PL3079671T3 (pl)
PT (1) PT3079671T (pl)
RS (1) RS56738B1 (pl)
SG (1) SG11201604741UA (pl)
SI (1) SI3079671T1 (pl)
TN (1) TN2016000230A1 (pl)
WO (1) WO2015086643A1 (pl)
ZA (1) ZA201603903B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013030830B1 (pt) 2011-06-01 2019-12-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo de preparação de estetrol
KR101957937B1 (ko) 2011-06-01 2019-03-14 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ME02723B (me) * 2011-08-11 2017-10-20 Estetra Sprl Upotreba estetrola kao kontraceptivnog sredstva u hitnim slučajevima
ES2877476T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
ES2877186T3 (es) * 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
PL3310333T3 (pl) * 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) * 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
UA126746C2 (uk) * 2018-02-07 2023-01-18 Естетра Спрл Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
ATE350041T1 (de) * 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
EP1390041B1 (en) * 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
DE60223795T2 (de) * 2001-05-23 2008-11-27 Pantarhei Bioscience B.V. Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
EA007599B1 (ru) * 2002-02-21 2006-12-29 Шеринг Акциенгезельшафт Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
ES2659316T3 (es) * 2006-06-08 2018-03-14 Allergan Pharmaceuticals International Limited Procedimientos para administrar formas de dosificación sólidas de etinilestradiol y profármacos del mismo con biodisponibilidad mejorada
CL2007003429A1 (es) * 2006-11-29 2008-04-11 Wyeth Corp Tableta bi-capa que comprende una primera capa con al menos un estrogeno y una segunda capa con uno o mas agentes terapeuticos seleccionados entre un modulador selectivo del receptor de estrogeno y un agente progestacional; proceso de produccion, uti
EP2124900B1 (en) * 2006-12-20 2014-12-03 Teva Women's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
MX2009007254A (es) * 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
US8367647B2 (en) 2007-06-21 2013-02-05 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
DE102009007771B4 (de) * 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) * 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens

Also Published As

Publication number Publication date
SI3079671T1 (en) 2018-04-30
PT3079671T (pt) 2017-11-24
CA2932855A1 (en) 2015-06-18
JP6447931B2 (ja) 2019-01-09
RS56738B1 (sr) 2018-03-30
US9987287B2 (en) 2018-06-05
US20180117063A1 (en) 2018-05-03
SG11201604741UA (en) 2016-07-28
CN105979935B (zh) 2019-07-26
AU2014363599B2 (en) 2019-10-31
MX369035B (es) 2019-10-25
JP2016540021A (ja) 2016-12-22
EP3079671B1 (en) 2017-10-25
EA201691226A1 (ru) 2016-10-31
HUE035848T2 (en) 2018-05-28
TN2016000230A1 (en) 2017-10-06
NO3079671T3 (pl) 2018-03-24
US9884064B2 (en) 2018-02-06
EP3079671A1 (en) 2016-10-19
MA39105A1 (fr) 2017-04-28
IL246082B (en) 2018-03-29
NZ720906A (en) 2022-04-29
CA2932855C (en) 2022-07-19
MA39105B1 (fr) 2018-05-31
WO2015086643A1 (en) 2015-06-18
BR112016013502B1 (pt) 2021-05-11
LT3079671T (lt) 2018-02-12
KR20160102212A (ko) 2016-08-29
MX2016007595A (es) 2016-11-28
US20160310506A1 (en) 2016-10-27
HRP20180129T1 (hr) 2018-02-23
CL2016001411A1 (es) 2016-11-11
DK3079671T3 (en) 2017-12-11
BR112016013502A2 (pt) 2018-07-03
IL246082A0 (en) 2016-07-31
CY1119817T1 (el) 2018-06-27
EA032306B1 (ru) 2019-05-31
ES2655076T3 (es) 2018-02-16
CN105979935A (zh) 2016-09-28
ZA201603903B (en) 2018-07-25
KR102265150B1 (ko) 2021-06-16
AU2014363599A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
ZA201603903B (en) Orally disintegrating solid dosage unit containing an estetrol component
ZA201601604B (en) Comminuting device
SG10201708409VA (en) Medicament device
PL2857103T3 (pl) Urządzenie rozdrabniające
PL3044840T3 (pl) Urządzenie rozładowujące
HK1223825A1 (zh) 包含阿曲生坦的穩定化藥物劑型
HK1223833A1 (zh) 藥物劑型
ZA201603463B (en) An inhalable medicament
EP2968179A4 (en) RETARD-PRESENTATIONS
HK1220139A1 (zh) 口腔崩解片
IL245760A0 (en) Inhalation medicine
GB201305103D0 (en) An oral dosage form
GB201413253D0 (en) Solid dosage form
AU355916S (en) Telescopic chute
GB201404271D0 (en) Superforwarding processor
GB201320786D0 (en) Medicament
GB201314860D0 (en) Processor